Health‐related quality of life ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Scar severity assessed by health professionals · people with keloid scars
1 finding from 1 review
Scar severity validated by participants · people with keloid scars
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with keloid scars
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain assessed using a 5‐point scale defined by study authors (0 = none, 4 = severe) · people with keloid scars
1 finding from 1 review
no estimate extracted
1 study · 5 participants
Very low
Adherence · people with keloid scars
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with keloid scars
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in QoL SNOT‐20 · children and adults diagnosed with cystic fibrosis and chronic rhinosinusitis with nasal polyposis
1 finding from 1 review
Complications of surgery · children and adults diagnosed with cystic fibrosis and chronic rhinosinusitis with nasal polyposis
1 finding from 1 review
FEV1 % predicted: absolute change from baseline · children and adults diagnosed with cystic fibrosis and chronic rhinosinusitis with nasal polyposis
1 finding from 1 review
Eradication of bacterial infection · children and adults diagnosed with cystic fibrosis and chronic rhinosinusitis with nasal polyposis
1 finding from 1 review
Clinical improvement(visual analogue scale) · children and adults diagnosed with cystic fibrosis and chronic rhinosinusitis with nasal polyposis
1 finding from 1 review
Pulmonary exacerbations · children and adults diagnosed with cystic fibrosis and chronic rhinosinusitis with nasal polyposis
1 finding from 1 review
All‐cause mortality · children and adults diagnosed with cystic fibrosis and chronic rhinosinusitis with nasal polyposis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failed apnea reduction · treatment of apnea
Doxapram showed no clear difference in 1a. Failed apnea reduction after 2–7 days – doxapram compared to no… compared with no treatment, placebo, methylxanthine (including theophylline,… (low certainty).
3 findings from 1 review
RR 0.45 [0.2, 1.05]
1 study · 21 participants
Low
RR 1.35 [0.53, 3.45]
4 studies · 84 participants
Very low
RR 0.08 [0.01, 1.17]
1 study · 10 participants
Very low
4a.Death at any time during initial hospitalization – doxapram compared to no treatment for the treatment of apnea · treatment of apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
4b. Death at any time during initial hospitalization – doxapram compared to alternative treatment for the treatment of apnea · treatment of apnea
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
5a. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to no treatment for the treatment of apnea · treatment of apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
5b. Moderate‐to‐severe neurodevelopmental disability or intellectual impairment after 2 years of age – doxapram compared to alternative treatment for the treatment of apnea · treatment of apnea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found